Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065));Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Cell

Volumn 165, Issue 1, 2016, Pages 35-44

  Hugo, Willy ^a,b   Zaretsky, Jesse M ^b   Sun, Lu ^a,b   Song, Chunying ^a,b   Moreno, Blanca Homet ^a   Hu Lieskovan, Siwen ^a   Berent Maoz, Beata ^a   Pang, Jia ^a   Chmielowski, Bartosz ^a   Cherry, Grace ^a   Seja, Elizabeth ^a   Lomeli, Shirley ^a,b   Kong, Xiangju ^a,b   Kelley, Mark C ^c   Sosman, Jeffrey A ^c   Johnson, Douglas B ^c   Ribas, Antoni ^a,b   Lo, Roger S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; BRCA2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TRANSCRIPTOME;

ADVANCED CANCER; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; ENZYME INHIBITION; EXOME; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; HUMAN TISSUE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; TRANSCRIPTOMICS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MELANOMA; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRCA2 PROTEIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSCRIPTOME;

EID: 84961221351     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.01.010     Document Type: Erratum

References (45)

1. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
2. Cancer Genome Atlas Network Genomic Classification of Cutaneous Melanoma Cell 161 2015 1681 1696
3. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 2013 43 49
4. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
5. L. Chen, D.L. Gibbons, S. Goswami, M.A. Cortez, Y.H. Ahn, L.A. Byers, X. Zhang, X. Yi, D. Dwyer, W. Lin, and et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression Nat. Commun. 5 2014 5241
6. L. Chen, J.V. Heymach, F.X. Qin, and D.L. Gibbons The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression OncoImmunology 4 2015 e1002731
7. F. Favero, T. Joshi, A.M. Marquard, N.J. Birkbak, M. Krzystanek, Q. Li, Z. Szallasi, and A.C. Eklund Sequenza: Allele-specific copy number and mutation profiles from tumor sequencing data Ann. Oncol. 26 2015 64 70
8. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. Joseph, J.S. Weber, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
9. S. Hänzelmann, R. Castelo, and J. Guinney GSVA: Gene set variation analysis for microarray and RNA-seq data BMC Bioinformatics 14 2013 7
10. E. Hodis, I.R. Watson, G.V. Kryukov, S.T. Arold, M. Imielinski, J.P. Theurillat, E. Nickerson, D. Auclair, L. Li, C. Place, and et al. A landscape of driver mutations in melanoma Cell 150 2012 251 263
11. K.S. Hoek, O.M. Eichhoff, N.C. Schlegel, U. Döbbeling, N. Kobert, L. Schaerer, S. Hemmi, and R. Dummer In vivo switching of human melanoma cells between proliferative and invasive states Cancer Res. 68 2008 650 656
12. W.K. Holloman Unraveling the mechanism of BRCA2 in homologous recombination Nat. Struct. Mol. Biol. 18 2011 748 754
13. I. Hoof, B. Peters, J. Sidney, L.E. Pedersen, A. Sette, O. Lund, S. Buus, and M. Nielsen NetMHCpan, a method for MHC class I binding prediction beyond humans Immunogenetics 61 2009 1 13
14. A. Hoos, J.D. Wolchok, R.W. Humphrey, and F.S. Hodi CCR 20th Anniversary Commentary: Immune-Related Response Criteria - Capturing Clinical Activity in Immuno-Oncology Clin. Cancer Res. 21 2015 4989 4991
15. W. Huang, B.T. Sherman, and R.A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat. Protoc. 4 2009 44 57
16. W. Huang, B.T. Sherman, and R.A. Lempicki Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res. 37 2009 1 13
17. W. Hugo, H. Shi, L. Sun, M. Piva, C. Song, X. Kong, G. Moriceau, A. Hong, K.B. Dahlman, D.B. Johnson, and et al. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance Cell 162 2015 1271 1285
18. M.S. Inkeles, P.O. Scumpia, W.R. Swindell, D. Lopez, R.M. Teles, T.G. Graeber, S. Meller, B. Homey, J.T. Elder, M. Gilliet, and et al. Comparison of molecular signatures from multiple skin diseases identifies mechanisms of immunopathogenesis J. Invest. Dermatol. 135 2015 151 159
19. E. Karosiene, M. Rasmussen, T. Blicher, O. Lund, S. Buus, and M. Nielsen NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ Immunogenetics 65 2013 711 724
20. D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, and S.L. Salzberg TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions Genome Biol. 14 2013 R36
21. D.C. Koboldt, Q. Zhang, D.E. Larson, D. Shen, M.D. McLellan, L. Lin, C.A. Miller, E.R. Mardis, L. Ding, and R.K. Wilson VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing Genome Res. 22 2012 568 576
22. D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, and et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency N. Engl. J. Med. 372 2015 2509 2520
23. C. Liu, X. Yang, B. Duffy, T. Mohanakumar, R.D. Mitra, M.C. Zody, and J.D. Pfeifer ATHLATES: Accurate typing of human leukocyte antigen through exome sequencing Nucleic Acids Res. 41 2013 e142
24. M.P. Mak, P. Tong, L. Diao, R.J. Cardnell, D.L. Gibbons, W.N. William, F. Skoulidis, E.R. Parra, J. Rodriguez-Canales, I.I. Wistuba, and et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Clin. Cancer Res. 22 2016 609 620
25. D.J. McCarthy, Y. Chen, and G.K. Smyth Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation Nucleic Acids Res. 40 2012 4288 4297
26. A. Mitchell, H.Y. Chang, L. Daugherty, M. Fraser, S. Hunter, R. Lopez, C. McAnulla, C. McMenamin, G. Nuka, S. Pesseat, and et al. The InterPro protein families database: The classification resource after 15 years Nucleic Acids Res. 43 2015 D213 D221
27. G.T. Motz, and G. Coukos The parallel lives of angiogenesis and immunosuppression: Cancer and other tales Nat. Rev. Immunol. 11 2011 702 711
28. M. Nielsen, C. Lundegaard, T. Blicher, K. Lamberth, M. Harndahl, S. Justesen, G. Røder, B. Peters, A. Sette, O. Lund, and S. Buus NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence PLoS ONE 2 2007 e796
29. W. Peng, J.Q. Chen, C. Liu, S. Malu, C. Creasy, M.T. Tetzlaff, C. Xu, J.A. McKenzie, C. Zhang, X. Liang, and et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Discov. 6 2016 202 216
30. A.H. Ramos, L. Lichtenstein, M. Gupta, M.S. Lawrence, T.J. Pugh, G. Saksena, M. Meyerson, and G. Getz Oncotator: Cancer variant annotation tool Hum. Mutat. 36 2015 E2423 E2429
31. N.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, and et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 2015 124 128
32. A. Roberts, C. Trapnell, J. Donaghey, J.L. Rinn, and L. Pachter Improving RNA-Seq expression estimates by correcting for fragment bias Genome Biol. 12 2011 R22
33. M. Schäfer, and S. Werner Cancer as an overhealing wound: An old hypothesis revisited Nat. Rev. Mol. Cell Biol. 9 2008 628 638
34. P. Sharma, and J.P. Allison Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential Cell 161 2015 205 214
35. H. Shi, W. Hugo, X. Kong, A. Hong, R.C. Koya, G. Moriceau, T. Chodon, R. Guo, D.B. Johnson, K.B. Dahlman, and et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov. 4 2014 80 93
36. A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, L.A. Walsh, M.A. Postow, P. Wong, T.S. Ho, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N. Engl. J. Med. 371 2014 2189 2199
37. A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles Proc. Natl. Acad. Sci. USA 102 2005 15545 15550
38. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
39. E. Tran, M. Ahmadzadeh, Y.C. Lu, A. Gros, S. Turcotte, P.F. Robbins, J.J. Gartner, Z. Zheng, Y.F. Li, S. Ray, and et al. Immunogenicity of somatic mutations in human gastrointestinal cancers Science 350 2015 1387 1390
40. C. Trapnell, A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L. Salzberg, J.L. Rinn, and L. Pachter Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks Nat. Protoc. 7 2012 562 578
41. P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
42. E.M. Van Allen, D. Miao, B. Schilling, S.A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M.H. Foppen, S.M. Goldinger, and et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Science 350 2015 207 211
43. T. Voron, E. Marcheteau, S. Pernot, O. Colussi, E. Tartour, J. Taieb, and M. Terme Control of the immune response by pro-angiogenic factors Front. Oncol. 4 2014 70
44. E.J. Wherry T cell exhaustion Nat. Immunol. 12 2011 492 499
45. J.D. Wolchok, A. Hoos, S. O'Day, J.S. Weber, O. Hamid, C. Lebbé, M. Maio, M. Binder, O. Bohnsack, G. Nichol, and et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria Clin. Cancer Res. 15 2009 7412 7420